

## CLAIMS

1. A combination comprising a therapeutically non-effective dose of paroxetine or physiologically acceptable salts or solvates thereof and a therapeutically non-effective dose of 2-(S)-(4-Fluoro-2-methyl-phenyl)-piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methyl-amide or physiologically acceptable salts or solvates thereof.  
5
2. A combination as claimed in claim 1 wherein the paroxetine is present as its hydrochloride hemihydrate salt and 2-(S)-(4-Fluoro-2-methyl-phenyl)-piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methyl-amide is present as its methansulphonate salt.  
10
3. A combination as claimed in claim 1 or claim 2 comprising paroxetine or physiologically salts or solvates thereof in an amount from 1 to 10 mg (measured as the free base).  
15
4. A combination as claimed in any claims 1 to 3 comprising paroxetine or physiologically salts or solvates thereof in an amount from 3.5 to 7.5 mg (measured as the free base).  
20
5. A combination as claimed in any claims 1 to 4 comprising 2-(S)-(4-Fluoro-2-methyl-phenyl)-piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methyl-amide or physiologically salts or solvates thereof in an amount from 1 to 15 mg (measured as the free base).  
25
6. A combination as claimed in any claims 1 to 5 comprising 2-(S)-(4-Fluoro-2-methyl-phenyl)-piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methyl-amide or physiologically salts or solvates thereof in an amount from 5 to 15 mg (measured as the free base).  
30
7. A combination as claimed in any claims 1 to 6 comprising 2-(S)-(4-Fluoro-2-methyl-phenyl)-piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methyl-amide or physiologically salts or solvates thereof in an amount from 7 to 15 mg (measured as the free base).  
35

8. A combination as claimed in any claims 1 to 7 comprising paroxetine or physiologically salts or solvates thereof in an amount from 1 to 10 mg (measured as the free base) and 2-(S)-(4-Fluoro-2-methyl-phenyl)-piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methyl-amide or physiologically salts or solvates thereof in an amount from 1 to 15 mg (measured as the free base).
9. A combination as claimed in any claims 1 to 8 comprising paroxetine or physiologically salts or solvates thereof in an amount from 1 to 10 mg (measured as the free base) and 2-(S)-(4-Fluoro-2-methyl-phenyl)-piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methyl-amide or physiologically salts or solvates thereof in an amount from 5 to 15 mg (measured as the free base).
10. A combination as claimed in any claims 1 to 9 comprising paroxetine or physiologically salts or solvates thereof in an amount from 1 to 10 mg (measured as the free base) and 2-(S)-(4-Fluoro-2-methyl-phenyl)-piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methyl-amide or physiologically salts or solvates thereof in an amount from 7 to 15 mg (measured as the free base).
11. A combination as claimed in any claims 1 to 10 comprising paroxetine or physiologically salts or solvates thereof in an amount from 3.5 to 7.5 mg (measured as the free base) and 2-(S)-(4-Fluoro-2-methyl-phenyl)-piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methyl-amide or physiologically salts or solvates thereof in an amount from 1 to 15 mg (measured as the free base).
12. A combination as claimed in any claims 1 to 11 comprising paroxetine or physiologically salts or solvates thereof in an amount from 3.5 to 7.5 mg (measured as the free base) and 2-(S)-(4-Fluoro-2-methyl-phenyl)-piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methyl-amide or physiologically salts or solvates thereof in an amount from 5 to 15 mg (measured as the free base).

13. A combination as claimed in any claims 1 to 12 comprising paroxetine or physiologically salts or solvates thereof in an amount from 3.5 to 7.5 mg (measured as the free base) and 2-(S)-(4-Fluoro-2-methyl-phenyl)-piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methyl-amide or physiologically salts or solvates thereof in an amount from 7 to 15 mg (measured as the free base).

14 A combination as claimed in any claims 1 to 13 comprising paroxetine or physiologically acceptable salts or solvates thereof in an amount of 7.5 mg (measured as the free base) and comprising 2-(S)-(4-Fluoro-2-methyl-phenyl)-piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methyl-amide or physiologically acceptable salts or solvates thereof in an amount of 15 mg (measured as the free base).

15 15. A combination as claimed in any claims 1 to 14 comprising paroxetine or physiologically acceptable salts or solvates thereof in an amount of 3.75 mg (measured as the free base) and comprising 2-(S)-(4-Fluoro-2-methyl-phenyl)-piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methyl-amide or physiologically acceptable salts or solvates thereof in an amount of 15 mg (measured as the free base).

16. A combination as claimed in any claims 1 to 15 comprising paroxetine or physiologically acceptable salts or solvates thereof in an amount of 3.75 mg (measured as the free base) and comprising 2-(S)-(4-Fluoro-2-methyl-phenyl)-piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methyl-amide or physiologically acceptable salts or solvates thereof in an amount of 7.5 mg (measured as the free base).

17. A combination as claimed in any claims 1 to 16 comprising paroxetine or physiologically acceptable salts or solvates thereof in an amount of 7.5 mg (measured as the free base) and comprising 2-(S)-(4-Fluoro-2-methyl-phenyl)-piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methyl-amide or physiologically acceptable salts or solvates thereof in an amount of 7.5 mg (measured as the free base).

18. A combination according to any of claims 1 to 17 for use in the treatment and or prophylaxis of depression and /or anxiety.
- 5 19. A method for the treatment and/or prophylaxis of depression and/or anxiety in a mammal including a human, which comprises treating said animal with a therapeutically effective amount of a combination as claimed in any of claims 1 to 17.
- 10 20. A pharmaceutical formulation comprising a combination according to any of the claims 1 to 17 together with one or more pharmaceutically acceptable carriers or excipients.
- 15 21. The use of a combination according to any claims 1 to 17 in the manufacture of a therapeutically effective medicament for simultaneous or sequential administration for the treatment and/or prophylaxis of depression and /or anxiety.